OncoSec Medical to Present New Clinical Data at Melanoma Bridge 2014
November 05 2014 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will present new
data from clinical studies evaluating the Company’s ImmunoPulse
immunotherapy in patients with melanoma at Melanoma Bridge 2014.
The event is scheduled to take place at the Royal Continental Hotel
in Naples, Italy from December 3-6, 2014.
OncoSec’s Chief Medical Officer, Mai H. Le, M.D., commented: “We
are looking forward to a great Melanoma Bridge meeting in December
and are particularly excited to present both our long-term
follow-up data from the Phase 1 trial and the final overall
response data from the recently completed Phase 2 study in
metastatic melanoma.”
Robert H. Pierce, M.D., Chief Scientific Officer, added “The
positive findings from these monotherapy trials really set the
stage for our next, critical study in melanoma – testing the
combination of IL-12 gene transfer with an anti-PD1/PDL1
therapeutic.”
Data from the two clinical studies evaluating the safety and
efficacy of intratumoral electroporation of plasmid interleukin-12
in patients with metastatic melanoma will be featured in separate
abstract discussion sessions.
Abstract: Long-term overall survival from a phase I trial using
intratumoral plasmid interleukin-12 with electroporation in
patients with melanoma (Adil Daud, Kathryn Toshimi Takamura, Tu
Diep, Richard Heller, Robert H. Pierce).
When: Thursday, December 4th, 2014. 6:05 PM CET
Abstract: Intratumoral electroporation of plasmid
interleukin-12: efficacy and biomarker analyses from a phase 2
study in melanoma (OMS-I100) (Adil Daud, Alain Algazi, Michelle
Ashworth, Michael Buljan, Kathryn Toshimi Takamura, Tu Diep, Robert
H. Pierce, Shailender Bhatia).
When: Friday, December 5th, 2014. 5:40 PM CET
About Melanoma Bridge 2014
Melanoma Bridge 2014 aims to achieve a broad-based participation
by various groups and societies sharing a clinical or basic
interest in the immunology and the biology of the cancer
microenvironment. The Scientific Board of Melanoma Bridge includes
well-known experts from around the world covering a variety of
different areas and specialties. The event is being jointly
organized by Istituto Nazionale Tumori Fondazione "G. Pascale",
Fondazione Melanoma Onlus and Sidra Medical and Research Center,
together with the Society for Immunotherapy of Cancer (SITC). For
more information, please visit: http://www.melanomabridge.org
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse intratumoral cancer immunotherapy. OncoSec
Medical's core technology is designed to
enhance the local delivery and uptake of DNA IL-12 and
other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of
various skin cancers, as well as the potential to initiate a
systemic immune response without the systemic toxicities associated
with other treatments. OncoSec's lead program evaluating
ImmunoPulse for the treatment of metastatic melanoma is currently
in Phase 2 development, and is being conducted in collaboration
with several prominent academic medical centers. As the company
continues to evaluate ImmunoPulse in its current indications, it is
also focused on identifying and developing new immune-targeting
agents, investigating additional tumor indications, and evaluating
combination-based immunotherapy approaches. For more information,
please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Jordyn
Kopin855-662-6732investors@oncosec.comorPublic Relations:Dian
Griesel, Int’l.Laura Radocaj212-825-3210lradocaj@dgicomm.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024